Karyn A. Goodman
Advanced in Radiation Sickness

Dr. Karyn A. Goodman

Radiation Oncology
Icahn School Of Medicine At Mount Sinai
1 Gustave L Levy Pl, 
New York, NY 
Advanced in Radiation Sickness
Icahn School Of Medicine At Mount Sinai
1 Gustave L Levy Pl, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karyn Goodman is a Radiation Oncologist in New York, New York. Dr. Goodman is rated as an Advanced provider by MediFind in the treatment of Radiation Sickness. Her top areas of expertise are Anal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Her clinical research consists of co-authoring 217 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in CA
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1 Gustave L Levy Pl, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body Radiation Therapy (SBRT) in Refractory Metastatic MSS (Microsatellite Stable) Colorectal Cancer With Liver Metastases
Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body Radiation Therapy (SBRT) in Refractory Metastatic MSS (Microsatellite Stable) Colorectal Cancer With Liver Metastases
Enrollment Status: Withdrawn
Publish Date: December 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: December 19, 2022
Intervention Type: Drug, Radiation
Study Drugs: FOLFIRINOX, Gemcitabine
Study Phase: Phase 1
View 7 Less Clinical Trials

217 Total Publications

Supporting the professional development of trial managers: how can you help?
Supporting the professional development of trial managers: how can you help?
Journal: Trials
Published: August 22, 2025
Similar Doctors
Chandan Guha
Distinguished in Radiation Sickness
Dr. Chandan Guha
Radiation Oncology
Distinguished in Radiation Sickness
Dr. Chandan Guha
Radiation Oncology

Montefiore Einstein Comprehensive Cancer Center - Montefiore Medical Park

1625 Poplar Street, 
Bronx, NY 
 (6.7 miles away)
718-405-8550
Languages Spoken:
English
See accepted insurances

Exploring therapeutic potential of stem cell regeneration in the event of radiation insult. Dr. Guha is rated as a Distinguished provider by MediFind in the treatment of Radiation Sickness. His top areas of expertise are Anal Cancer, Radiation Sickness, Throat Cancer, and Laryngeal Cancer.

Experienced in Radiation Sickness
Dr. Joseph S. Cirrone
Radiation Oncology
Experienced in Radiation Sickness
Dr. Joseph S. Cirrone
Radiation Oncology

North Shore Hematology Oncology Associates PC

181 N Belle Mead Rd, 
East Setauket, NY 
 (45.8 miles away)
631-246-5860
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Cirrone is a Radiation Oncologist in East Setauket, New York. Dr. Cirrone is rated as a Distinguished provider by MediFind in the treatment of Radiation Sickness. His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Cervical Cancer, and Neuroendocrine Carcinoma of the Cervix.

Experienced in Radiation Sickness
Dr. Paul Youn
Radiation Oncology
Experienced in Radiation Sickness
Dr. Paul Youn
Radiation Oncology

North Shore Hematology Oncology Associates PC

285 Sills Rd, Bldg 17, 
East Patchogue, NY 
 (51.2 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances

Paul Youn is a Radiation Oncologist in East Patchogue, New York. Dr. Youn is rated as an Advanced provider by MediFind in the treatment of Radiation Sickness. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goodman's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile